[1] ADAMU M A,WECK M N,GAO L,et al.Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies[J]. Eur J Epidemiol,2010,25(7):439-448. [2] ADAMU M A,WECK M N,ROTHENBACHER D,et al. Incidence and risk factors for the development of chronic atrophic gastritis: five year follow-up of a population-based cohort study[J]. Int J Cancer,2011,128(7): 1652-1658. [3] 李慕然,刘艳迪,唐涛,等.幽门螺杆菌和慢性胃炎胃黏膜病理变化的关系研究[J]. 天津医药,2015,43(1): 54-56. [4] 李琼,刘晏,吴坚炯.慢性萎缩性胃炎的治疗进展[J]. 中医学报,2013,28(1): 114-116. [5] 徐斌,黄玉凯,周进.慢性萎缩性胃炎的胃镜下表现与病理诊断对照分析[J]. 中华全科医学,2014,9(12):1388-1390. [6] 张晓倩,鲁重美.幽门螺杆菌感染、慢性萎缩性胃炎与胃癌[J]. 临床消化病杂志,2016,3(28):192-195. [7] 周军,车虎森,何雪琴,等.血清胃蛋白酶原I、II在慢性萎缩性胃炎筛查中的应用价值[J]. 疑难病杂志,2014,13(10):1073-1075. [8] 方小鹤,赵平,王江滨.血清胃泌素17在慢性萎缩性胃炎患者中的表达水平及意义[J]. 中国老年学杂志,2015,35(5):1290-1291. [9] 中华医学会消化病学分会. 中国慢性胃炎共识意见(2012年,上海)[J]. 中华消化杂志,2013,33(1):5-16. [10] 唐建林.慢性萎缩性胃炎伴肠上皮化生患者200例临床分析[J]. 中国医学工程,2012,20(1):145,147. [11] AJDARKOSH H,SOHRABI M,MORADNIANI M,et al. Prevalence of gastric precancerous lesions among chronic dyspeptic patients and related common risk factors[J]. Eur J Cancer Prev,2015,24(5): 400-406. [12] 王建国.影响慢性胃炎发展为胃癌的相关因素分析[J]. 海南医学, 2015,26(18): 2694-2696. [13] 吴共发,黄绮亭,邱丽浈,等.幽门螺旋杆菌感染者胃GPX1和SOD1表达的免疫组织化学研究[J]. 现代医院,2017,17(7):1011-1012,1016. [14] 王暖凤,初海坤,黄树民,等.慢性萎缩性胃炎患者临床流行病学分析[J]. 中国公共卫生,2017,7(33):1109-1111. [15] 江堤,苏剑东,张莉等.血清胃蛋白酶原对胃癌筛查价值的探讨[J]. 广州医药,2016,47(1):24-27. [16] 周海平.胃蛋白酶原Ⅰ联合胃泌素 -17 检测对慢性萎缩性胃炎发病部位及胃癌进展时期的预测价值[J]. 中国当代医药,2014,21(25):126-128. [17] AGRÉUS KUIPERS.Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers[J]. Scand J Gastroenterol,2012,47(12): 1525. [18] GHOSHAL U C,KUMAR S,KRISHNANI N,et al. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-Ⅰ,pepsinogen-Ⅱ and gastrin-17 levels in a low incidence area of gastric cancer endemic for H.pylori infection[J]. Trop Gastroenterol,2011,32(4):292-298. |